My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone (HGH)
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Livewell Pharmaceuticals Livewell Pharmaceuticals
Tirzepatide
Tirzepatide - Livewell Pharmaceuticals

Tirzepatide - Livewell Pharmaceuticals

Brand:
Livewell Pharmaceuticals
Category:
Peptides
Substance:
Tirzepatide
Package:
5 mg
Price:
$130.00 - $130.00
See options
Product Overview
Approved in 2022, tirzepatide (Mounjaro®) is a dual GIP/GLP-1 receptor agonist designed for patients with Type 2 Diabetes. It delivers superior glycemic control and weight loss benefits compared to existing GLP-1 therapies. Clinical data from the SURPASS-4 study highlighted its reduced mortality rates versus insulin glargine during the pandemic. With its dual-action design and strong efficacy, tirzepatide is a leading candidate for future trials targeting obesity and other metabolic complications.
References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tirzepatide by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.

Products
Active Substances
  • Tirzepatide
 About Product
Tirzepatide
Livewell Pharmaceuticals
USA
$130.00
Show more
Reviews
Leave Review
FAQ
Is Tirzepatide a once-weekly treatment?
Yes, Tirzepatide is designed for once-weekly use, helping patients manage Type 2 Diabetes more conveniently.
References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.

Does Tirzepatide lower HbA1c levels?
Tirzepatide has shown strong reductions in HbA1c in clinical trials, making it effective for glycemic control.
References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.

Can Tirzepatide be used instead of insulin?
In trials, Tirzepatide outperformed insulin glargine in reducing death rates during the COVID-19 pandemic.
References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.